Institute Of Cancer Research, United Kingdom

This phase 3 trial is for postmenopausal women with a common type of breast cancer that has a high chance of returning. Participants receive either standard hormone therapy alone or with the addition of abemaciclib, a targeted drug that blocks cancer cell growth. The goal is to s…

This phase 2 trial tests a new drug (ceralasertib) alone or with either a PARP inhibitor (olaparib) or an immunotherapy (durvalumab) in 174 people with advanced gynaecological cancers that have returned. The study looks at how well these combinations shrink tumors, especially in …

This early-stage study tests two drugs together—tepotinib and pembrolizumab—in people with advanced non-small cell lung cancer. The goal is to see if adding tepotinib can help pembrolizumab work better, especially in tumors that don't respond well to immunotherapy alone. About 19…

This early-stage trial tests a combination of two experimental drugs, defactinib and VS-6766, in people with advanced solid tumors that have not responded to standard treatments. The study includes patients with certain lung, ovarian, endometrial, or pancreatic cancers. The main …

This study looks at men with advanced prostate cancer that no longer responds to hormone therapy. Researchers want to see if men with certain gene changes (in DNA repair genes) respond better to the chemotherapy drug carboplatin. Participants first get a genetic test, and those w…

This study looks at whether men with certain inherited gene changes (BRCA1, BRCA2, or mismatch repair genes) have a higher chance of getting prostate cancer. About 3,500 men aged 40-69 with or without these gene changes will get yearly PSA tests. The goal is to learn how often pr…

This study looks at the DNA of nearly 24,000 men with prostate cancer to find inherited genetic changes that increase risk. It focuses on younger men and those with a family history, where genes may play a bigger role. The goal is to better understand why some men get prostate ca…

This study looks at blood samples from 25 cancer patients receiving radiotherapy to find specific gene patterns that show how each person's body responds to radiation. Researchers will test these samples before and during treatment to identify markers that could help personalize …

This study looks at whether a man's genetic profile can help doctors decide who should be screened for prostate cancer. About 300 men aged 55-69 will have their genes checked and those with higher genetic risk will be offered a prostate biopsy. The goal is to see if this approach…